Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amyotrophic Lateral Sclerosis
Catalytic antioxidant, AEOL 10150, selected for development as ALS treatment
September 1st, 2003
Incara Pharmaceuticals Corp. (INCR) announced the selection of its catalytic antioxidant, AEOL 10150, for late-stage preclinical development to support an investigational new drug (IND) application for the treatment of amyotrophic lateral sclerosis (ALS). Assuming satisfactory completion of animal safety studies and completion of the remaining component of its recently announced financing, Incara intends to file the investigational new drug (IND) application in the second quarter of 2004. Allowance of the IND by the U.S. Food and Drug Administration (FDA) would permit Incara to initiate clinical trials. The clinical program will test the ability of AEOL 10150 treatment...
Source: Health & Medicine Week (2003-09-01)
|
